Diligence memo · auto-generated · as of July 2, 2026

Daya CNS, LLC

Daya CNS, LLC looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Daya CNS, LLC operates in Pharmaceuticals, based in SAINT LOUIS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Daya CNS, LLC has raised $228K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $228K on 2015-08-01.

Most recent recorded round closed around 2015-08-01.

Valuation (modeled)modeled

Provath models Daya CNS, LLC at approximately $11M (range $128K–$122M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.95× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era. Within the normal band (95% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 10.9 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 5% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 18% of those peers.

Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.